Exploring the Anticonvulsant Potential of Cannabaceae Family: A Focus on GABAergic Modulation and Epilepsy Treatment
DOI:
https://doi.org/10.52783/jns.v14.3541Keywords:
Anticonvulsant activity, Cannabaceae family, GABAergic modulation, Epilepsy, SeizureAbstract
This review explored the anticonvulsant potential of various species from the Cannabaceae family, including Cannabis sativa, Humulus lupulus, Celtis integrifolia, Celtis tournefortii, and Trema orientalis. Epilepsy is a complex neurological condition influenced by multiple factors such as genetics, structural abnormalities, infections, metabolic disturbances, and immune system dysfunctions. Phytochemicals like cannabidiol (CBD) and tetrahydrocannabinol (THC) from Cannabis sativa, along with other bioactive compounds from Humulus lupulus, have shown significant anticonvulsant effects by regulating GABAergic neurotransmission. Additionally, Celtis integrifolia and Celtis tournefortii have demonstrated potential in mitigating oxidative stress, a key factor in the onset of seizures. While these findings from preclinical studies are promising, the lack of extensive clinical trials limits their immediate application in treating epilepsy in humans. This review highlighted the necessity for further research focused on isolating active compounds, studying their pharmacokinetics, and conducting clinical trials to validate their potential as effective treatments for epilepsy.
Downloads
Metrics
References
Abdulwahid-Kurdi SJ. Detect Polyphenol and Fatty Acid Content of Two Wild Plants Collected in Mazne Sub-district, Kurdistan Region of Iraq. Current Research in Nutrition & Food Science. 2023 Apr 1;11(1).
Adam BA, Musa AL. Anticonvulsant screening of methanol stem bark extract of Celtis integrifolia Lam (Ulmaceae) in mice and chicks. Journal of International Research in Medical and Pharmaceutical Sciences. 2016;10(4):199-205.
Aghdash SN, Nasirifard S. Assessment of aqueous extract of Humulus lupulus effects on seizure induced by intraperitoneal injection of pentylenetetrazole in mice. Neurosci. J. Shefaye Khatam. 2015; 3:49-54.
Akyuz E, Lazarowski A, de Cabo C, Godlevsky LS, Shaikh MF, Doganyigit Z. Ion-channels in epilepsy. Frontiers in Neurology. 2023 Aug 10; 14:1263539.
Alivand S. Cone and leaf aqueous extract of Humulus Lupulus have neuroprotective and antiepileptogenic effects in mouse pentylenetetrazole kindling model. Pathobiology Research. 2022 Feb 10;25(2):30-7.
Anderson LL, Ametovski A, Lin Luo J, Everett-Morgan D, McGregor IS, Banister SD, Arnold JC. Cannabichromene, related phytocannabinoids, and 5-fluoro-cannabichromene have anticonvulsant properties in a mouse model of Dravet Syndrome. ACS chemical neuroscience. 2021 Jan 4;12(2):330-9. https://doi.org/10.1021/acschemneuro.0c00677
Anderson LL, Heblinski M, Absalom NL, Hawkins NA, Bowen MT, Benson MJ, Zhang F, Bahceci D, Doohan PT, Chebib M, McGregor IS. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British journal of pharmacology. 2021 Dec;178(24):4826-41. https://doi.org/10.1111/bph.15661
Anderson LL, Low IK, Banister SD, McGregor IS, Arnold JC. Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet syndrome. Journal of natural products. 2019 Nov 5;82(11):3047-55. https://doi.org/10.1021/acs.jnatprod.9b00600
Anderson LL, Low IK, McGregor IS, Arnold JC. Interactions between cannabidiol and Δ9‐tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. British Journal of Pharmacology. 2020 Sep;177(18):4261-74. https://doi.org/10.1111/bph.15181
Anderson LL, Udoh M, Everett-Morgan D, Heblinski M, McGregor IS, Banister SD, Arnold JC. Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. Journal of Cannabis Research. 2022 Dec; 4:1-9.
https://doi.org/10.1186/s42238-021-00113-w
Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Frontiers in plant science. 2016 Feb 4; 7:19.
Avanzini G, Franceschetti S. Mechanisms of epileptogenesis. The treatment of epilepsy. 2015 Oct 2:38-51.
Bautista JL, Yu S, Tian L. Flavonoids in Cannabis sativa: Biosynthesis, bioactivities, and biotechnology. ACS omega. 2021 Feb 18;6(8):5119-23.
Benkherouf AY. Nature's Brewery to Bedtime: The Role of Hops in GABAA Receptor Modulation and Sleep Promotion. arXiv preprint arXiv:2402.02129. 2024 Feb 3.
Benson MJ, Anderson LL, Low IK, Luo JL, Kevin RC, Zhou C, McGregor IS, Arnold JC. Evaluation of the possible anticonvulsant effect of Δ9-tetrahydrocannabinolic acid in murine seizure models. Cannabis and cannabinoid research. 2022 Feb 1;7(1):46-57. https://doi.org/10.1089/can.2020.0073
Bhattacharya S, Satyan K (1997a) Experimental methods for evaluation of psychotropic agents in rodents: I--Anti-anxiety agents. Indian journal of experimental biology 35:565–575
Bih CI, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct 1;12(4):699-730.
Blair RE, Deshpande LS, DeLorenzo RJ. Cannabinoids: is there a potential treatment role in epilepsy? Expert opinion on pharmacotherapy. 2015 Sep 2;16(13):1911-4.
Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A, GWEP1330 Study Group. A phase 2 randomized controlled trial of the efficacy and safety of cannabidivarin as add-on therapy in participants with inadequately controlled focal seizures. Cannabis and Cannabinoid Research. 2021 Dec 1;6(6):528-36. https://doi.org/10.1089/can.2020.0075
Busquets-Garcia A, Bains J, Marsicano G. CB1 receptor signalling in the brain: extracting specificity from ubiquity. Neuropsychopharmacology. 2018 Jan;43(1):4-20.
Carvill GL. Calcium channel dysfunction in epilepsy: gain of CACNA1E. Epilepsy Currents. 2019 May;19(3):199-201. https://doi.org/10.1177/1535759719845324
Chen JK, Chen J, Imig JD, Wei S, Hachey DL, Guthi JS, Falck JR, Capdevila JH, Harris RC. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. Journal of Biological Chemistry. 2008 Sep 5;283(36):24514-24.
Chen TS, Huang TH, Lai MC, Huang CW. The role of glutamate receptors in epilepsy. Biomedicines. 2023 Mar 4;11(3):783.
De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British journal of pharmacology. 2011 Aug;163(7):1479-94. https://doi.org/10.1111/j.1476-5381.2010.01166.x
Zanoli P, Zavatti M. Pharmacognostic and pharmacological profile of Humulus lupulus L. Journal of ethnopharmacology. 2008 Mar 28;116(3):383-96.
Sharma J, Gairola S, Gaur RD, Painuli RM, Siddiqi TO. Ethnomedicinal plants used for treating epilepsy by indigenous communities of sub-Himalayan region of Uttarakhand, India. Journal of Ethnopharmacology. 2013 Oct 28;150(1):353-70.
Waris A, Ullah A, Asim M, Ullah R, Rajdoula MR, Bello ST, Alhumaydhi FA. Phytotherapeutic options for the treatment of epilepsy: pharmacology, targets, and mechanism of action. Frontiers in Pharmacology. 2024 May 24; 15:1403232. https://doi.org/10.3389/fphar.2024.1403232
Gao K, Lin Z, Wen S, Jiang Y. Potassium channels and epilepsy. Acta Neurologica Scandinavica. 2022 Dec;146(6):699-707. https://doi.org/10.1111/ane.13695
Perucca E. The pharmacological treatment of epilepsy: recent advances and future perspectives. Acta Epileptologica. 2021 Sep 17;3(1):22. https://doi.org/10.1186/s42494-021-00055-z
Klein BD, Jacobson CA, Metcalf CS, Smith MD, Wilcox KS, Hampson AJ, Kehne JH. Evaluation of cannabidiol in animal seizure models by the Epilepsy Therapy Screening Program (ETSP). Neurochemical research. 2017 Jul; 42:1939-48. https://doi.org/10.1007/s11064-017-2287-8
Khan AA, Shekh‐Ahmad T, Khalil A, Walker MC, Ali AB. Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model. British journal of pharmacology. 2018 Jun;175(11):2097-115. https://doi.org/10.1111/bph.14202
Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, Russo E, Whalley BJ, Di Marzo V, Stephens GJ. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channel in vitro: potential for the treatment of neuronal hyperexcitability. ACS chemical neuroscience. 2014 Nov 19;5(11):1131-41. https://doi.org/10.1021/cn5000524
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology. 2016 Mar 1;15(3):270-8.
Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M. Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results. Epilepsia. 2018 Aug;59(8):1540-8. https://doi.org/10.1111/epi.14477
Hurley EN, Ellaway CJ, Johnson AM, Truong L, Gordon R, Galettis P, Martin JH, Lawson JA. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia. 2022 Jul;63(7):1736-47. https://doi.org/10.1111/epi.17247
Hill AJ, Weston SE, Jones NA, Smith I, Bevan SA, Williamson EM, Stephens GJ, Williams CM, Whalley BJ. Δ9‐Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia. 2010 Aug;51(8):1522-32. https://doi.org/10.1111/j.1528-1167.2010.02523.x
Goerl B, Watkins S, Metcalf C, Smith M, Beenhakker M. Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures. Epilepsy research. 2021 Jan 1; 169:106525 https://doi.org/10.1016/j.eplepsyres.2020.106525
McPartland JM, MacDonald C, Young M, Grant PS, Furkert DP, Glass M. Affinity and efficacy studies of tetrahydrocannabinolic acid A at cannabinoid receptor types one and two. Cannabis and cannabinoid research. 2017 May 1;2(1):87-95.. https://doi.org/10.1089/can.2016.0032
Udoh M, Bladen C, Heblinski M, Luo JL, Janve VS, Anderson LL, McGregor IS, Arnold JC. The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels. Frontiers in Pharmacology. 2022 Nov 1; 13:1048259. https://doi.org/10.3389/fphar.2022.1048259
Seo S, Song Y, Gu SM, Min HK, Hong JT, Cha HJ, Yun J. D-limonene inhibits pentylenetetrazole-induced seizure via adenosine A2A receptor modulation on GABAergic neuronal activity. International journal of molecular sciences. 2020 Dec 4;21(23):9277. https://doi.org/10.3390/ijms21239277
Wang CC, Ho YH, Hung CF, Kuo JR, Wang SJ. Xanthohumol, an active constituent from hope, affords protection against kainic acid-induced excitotoxicity in rats. Neurochemistry International. 2020 Feb 1; 133:104629.
Gray RA, Stott CG, Jones NA, et al (2020b) Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent. Cannabis Cannabinoid Res 5:145–149. https://doi.org/10.1089/can.2019.0028
Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology. 2019 Apr 1; 148:189-98. https://doi.org/10.1016/j.neuropharm.2019.01.002
Felipe CF, Albuquerque AM, de Pontes JL, de Melo JÍ, Rodrigues TC, de Sousa AM, Monteiro ÁB, Ribeiro AE, Lopes JP, de Menezes IR, de Almeida RN. Comparative study of alpha‐and beta‐pinene effect on PTZ‐induced convulsions in mice. Fundamental & Clinical Pharmacology. 2019 Apr;33(2):181-90. https://doi.org/10.1111/fcp.12416
Elisabetsky E, Brum LS, Souza DO. Anticonvulsant properties of linalool in glutamate-related seizure models. Phytomedicine. 1999 May 1;6(2):107-13. https://doi.org/10.1016/s0944-7113(99)80044-0
Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, Laux L, Marsh ED. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. Journal of child neurology. 2017 Jan;32(1):35-40. https://doi.org/10.1177/0883073816669450
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. New England Journal of Medicine. 2018 May 17;378(20):1888-97. https://doi.org/10.1056/NEJMoa1714631
Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Efficacy and tolerance of synthetic cannabidiol for treatment of drug-resistant epilepsy. Frontiers in Neurology. 2019 Dec 10; 10:1313.
Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, Saneto RP, Checketts D, Dunayevich E, Knappertz V, GWPCARE2 Study Group. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA neurology. 2020 May 1;77(5):613-21.
Huntsman RJ, Tang-Wai R, Alcorn J, Vuong S, Acton B, Corley S, Laprairie R, Lyon AW, Meier S, Mousseau DD, Newmeyer D. Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E study. Frontiers in neurology. 2019 Jul 3; 10:716. https://doi.org/10.3389/fneur.2019.00716
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
